New healthcare technology development project launched to improve patient outcome and the success rate of haematopoietic stem cell transplants (HSCT)

€3.5 million research and development programme is launched today to improve the success rate of stem cell transplants, including bone marrow transplants for Leukaemia patients. Professor Anne Dickinson, Haematological Sciences, Newcastle University, leads the programme in partnership with a consortium of 13 leading European clinical research institutes and biotech firms.

Known as StemDiagnostics, the consortium will aim to identify new bio-markers (indicators of transplant rejection and clinical complications) and develop medical diagnostic tests that will help practitioners to improve the success rate of allogeneic haematopoietic stem cell transplants (HSCT), treatments for life threatening medical conditions and cancers such as leukaemia, lymphoma and inherited immune disorders.

Around 7,000 such transplants take place throughout Europe each year, but the survival rate is low (40 – 60 per cent) and decreases rapidly with patient age. The application of HSCT therapy is also hampered by the lack of suitable matched donors: only 25 –30 per cent of patients find a compatible sibling donor.

Such transplants involve the use of bone marrow, peripheral blood stem cells and umbilical cord blood as stem cell sources. The project, which follows 3 year’s research by Professor Dickinson and the Consortium, aims to develop tests with the use of the latest bionano and lab-on-a-chip techniques provided by SMEs such as Orla Protein Technologies, also based in North East England. Cenamps, a Newcastle-based centre for emerging umbilical cord blood as stem cell sources. The project, which follows 3 year’s research by Professor Dickinson and the Consortium, aims to develop tests with the use of the latest bionano and lab-on-a-chip techniques provided by SMEs such as Orla Protein Technologies, also based in North East England. Cenamps, a Newcastle-based centre for emerging technologies, will handle commercialisation aspects of the project’s outcomes.

Professor Anne Dickinson, commented: “The project is the first of its kind to bring together research looking at a variety of different biomarkers – or indicators of post transplant complications. These include DNA and proteins. From this work, we hope to be able to develop new diagnostic tools using genomics, proteomics, in vitro bioassays and biochips, to aid in earlier clinical intervention by predicting any complications which may arise in our bone marrow transplant patients.”

StemDiagnostics will develop new proteomic, biological and genomic tests for predicting patient response prior to transplant and subsequently for monitoring of patient response to novel therapeutics for the most severe complication of HSCT – graft versus host disease (GvHD). The consortium aims to bring to the clinic the next generation of diagnostics tests for use in HSCT.
To meet this challenge, StemDiagnostics brings together five of European’s leading small and medium-sized enterprises (SMEs) with expertise in genomic and proteomic testing, diagnostic assay development and biochips, with clinical partners selected for their world-leading research in HSCT and access to clinical samples and patient groups. The SMEs include Mosaiques Diagnostics, Multimmune, IMGM Laboratories, Apotech and Orla Protein Technologies.

Shak Gohir, Business & Programme Manager at Cenamps, added: “We’re extremely excited to see such a life enhancing and life saving research being led from here - the North East of England. StemDiagnostics very much aligns with Cenamps’ core objectives to stimulate and connect research conducted in some Europe’s leading universities and research institutions to resolve issues and challenges that clearly address the real and wider needs of society.”

The programme is funded by the European Commission to the tune of €2.5M over next three years, through the EU Sixth Framework Programme under the Life Sciences and Health theme. The consortium provides for the remaining investment.

Shak Gohir
Business & Programme Manager

The future of China’s economy. Results of a recent survey can be found in Insight 5.

China has poured about 1.5 billion yuan (about $197 million) into the research and development of nanoscience and nanotechnology over the past 15 years. The number of patents they have filed for has increased from less than 1,000 in 2001 to more than 4,600 in March 2005. China is not just about manufacturing. China is moving up the value chain as is investing in R&D as a key economic and growth development strategy.

During 2006, the world's three largest spenders of R&D where the United States (US$330 billion) and China (US$136 billion) followed by Japan (US$130 billion). A 2006 study on global R&D by the Battelle Memorial Institute indicated that China has increased R&D spending annually about 17% over a 12-year period, compared to 4% to 5% for Europe and the United States. The key issue may not be just the investment in R&D in Europe as R&D alone does not increase profits. It is also converting the the results of R&D into commercialised patents, start-up, products and services.

The Chinese economy has enjoyed four consecutive years of at least 10% growth. China's economy expanded by 10.7% in 2006. New economic research reveals businesses in Europe and the US are very scared of the impact but ill prepared to act and lag behind their Asian counterparts on ambitions for the China (中華人民共和國) market. Over 700 business leaders, government officials, leading academics and futurists from across 60 countries were polled in the first worldwide survey to gather views and expectations of China’s global impact over the period to 2020.

The survey conducted by business think tanks Global Futures and Foresight (GFF) and Fast Future provides rich insight into how business attitudes and ambitions for the China market are evolving across five continents. The report ‘The Future of China’s Economy, The Path to 2020 – Opportunities, Challenges and Uncertainties’ published on the 22 March 2007 provides a ‘wake up call’ to the Western business world, warning that to thrive in the changing global economy action must be taken now to make China a key element in future business strategies.

Graham Leach, Chief Economist and Director of Policy for the UK Institute of Directors says, “For UK and Western businesses to stay competitive in the global marketplace, China has to be a key component of their strategy. This study highlights very clearly that business leaders in the west now understand the scale and long term potential of China’s economy and they recognise the massive impact China will have in their markets globally. Despite this, many are still unwilling to respond, hesitant in their China strategies or simply unsure of what to do. It is now time to act on these concerns, start learning about the Chinese marketplace, drawing on the experience of those already doing business in China and actively embracing the opportunity that China presents.”

Key findings of the survey can be found in Insight 5....click here to read more...

You may also find interesting the results of a study conducted by Booz Allen's - Smart Spenders: Global Innovation 1000. This study and report highlights a small group of high-leverage innovative firms who out perform the industry. They are able to reduce R&D investment and still innovate more successfully than their competitors. "Money simply cannot buy innovation". Information on the study has been published by Booz Allen in Insight 4 .... to read the article click here.

Shak Gohir
Business & Progamme Manager

PETeC ground-breaking marks start of North East plastic electronics revolution

Cenamps, in partnership with the Centre for Process Innovation (CPI), hosted a groundbreaking ceremony for PETeC on 27th July 2007. PETeC, a unique plastics electronics technology centre, is set to establish North East England as a global leader in the application of plastic electronics.

The first spade was inserted into the ground starting construction of the £10m project at NETPark, County Durham, where the new facility is to be based.

PETeC will be established as a national prototyping operation providing world-class facilities, services and expertise at the hub of a UK-wide network in plastic electronics. The state-of-the-art facilities will include high-tech clean rooms and laboratories, as well as production and testing equipment which will be available on an open access basis to meet the needs of industry.

PETeC will offer space, resource and expertise for companies to research and develop new technologies and their applications, prototyping and pre-competitive stage mini-manufacturing of products based on plastic electronics. These will include smart packaging, real-time smart packaging, real-time newspapers, intelligent signage, point-of-care medical diagnostic devices, novel drug delivery devices, printed electronics for consumer products, flexible solar cells and solid state lighting.

Dr Mike Pitkethly, CEO of Cenamps commented: “This centre will provide a bridge between the lab and the factory to facilitate the commercialisation of new products. With ever-increasing competition from places such as India and China, it is crucial that the UK continues to offer the world class facilities for developing plastic electronic products, and PETeC will be integral to the UK’s competitiveness in this emerging group of technologies”.

The project has been funded by One NorthEast, The Northern Way and the European Regional Development Fund.

For further information contact: enquiries@uk-petec.com

Career Opportunity: BioNano Commercialisation Manager with Cenamps

Cenamps is a unique company. We connect regional and national economic strategies with emerging technological capabilities and market drivers to help businesses to succeed through the innovation of high value processes, products and services. Due to the recent award of major technology projects and our subsequent, and continual, growth we are seeking to recruit four individuals to join our highly talented and dedicated team. We are seeking to hire a NanoBio Commercialisation Manager.

The successful candidate will actively lead the early-stage technology commercialisation activities of Cenamps BioNano research and innovation projects and be responsible for Cenamps IP portfolio and interests. Applicants must demonstrate experience in the innovation and commercialisation of emerging healthcare technologies such as lab-on-a-chip devices, biomaterials and sensors and/or other medical devices ideally gained by working in industry and will be skilled in focusing research and innovation activities in alignment with identified needs and market drivers.

The successful candidate will work on a number of high profile regional and European research projects, engaging closely with our academic and industrial partners to drive forward commercialisation strategies, uncover routes to market, identifying specific technologies requiring IP protection, publishing thought leadership articles and presenting at international conferences. Two of our high profile European projects aim to innovate new medical devices for diagnosing deep vein thrombosis (DVT) and improving patient outcomes from haematopoietic stem cell transplant (HSCT) treatment.

With an established network of contacts, the Commercialisation Manager will be adept at generating, shaping and following through on new project and business opportunities. Experience in proposal development, venture capital, government R&D grants and medical device regulations is strongly preferred, in addition to knowledge of the medical sciences and trends in the healthcare sector. Across a number of key industries including energy, health and chemicals, an important aspect of the opportunity will be to assist and mentor high-tech SMEs on technology innovation, investment sources, partner searching and commercialisation. Candidates with a MBA and PhD in relevant fields, with experience gained from industry, are strongly preferred.